LFSC F/M Emerald Life Sciences Innovation ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 48.03 | Day Range | 47.41 – 47.59 |
| 52-Week Range | 27.67 – 48.78 | Volume | 1.40K |
| Avg Volume | 4.11K | AUM | $74.7M (Aug 27, 2026) |
| Expense Ratio | 0.54% | Yield (TTM) | — |
| NAV | 32.18 | Premium/Discount | +47.86% indicative |
| Inception | Oct 21, 2024 | Holdings | — |
| Issuer | F/m | Exchange | NASDAQ |
| Category | Artificial Intelligence | Index Tracked | Not stated in source data |
| CUSIP | 74933W221 | ISIN | US74933W2219 |
| Management | Actively managed (per issuer description) | ||
About this ETF
LFSC seeks to invest in innovative life sciences companies that are expected to create value and long-term growth. The actively managed fund relies on a specialized and experienced team to research complex life sciences companies. It invests in US equity securities identified to have growth potential that meet the criteria of technological advancement, market disruption, or artificial intelligence. The broad life science field includes biotechnology, pharmaceutical, medical diagnostics and devices, healthcare services and technologies, and synthetic biology. Stock selection employs an extensive 10-step research process that includes reviews of publicly available and third-party information, peer reviews, financial and valuation models, internal research, surveys, as well as interviews and contact with management, industry and medical professionals, supply chain, and collaboration within the investment team. The fund may invest up to 20% in foreign companies listed on a US exchange.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +6.57% | +24.48% | +30.93% | +31.28% | +76.90% | — | — | — | +42.58% |
| Total return | +6.56% | +24.48% | +30.92% | +31.28% | +76.89% | — | — | — | +42.58% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.54% | Annual cost of a $10,000 investment | $54.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 40 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Travere Therapeutics Inc | TVTX | 8.25% | 165.89K | $10.9M |
| 2 | Spyre Therapeutics Inc | SYRE | 7.73% | 94.68K | $10.2M |
| 3 | Corcept Therapeutics Inc | CORT | 6.88% | 74.90K | $9.1M |
| 4 | Cogent Biosciences Inc | COGT | 6.52% | 233.78K | $8.6M |
| 5 | LivaNova PLC | LIVN | 6.24% | 104.63K | $8.2M |
| 6 | Mirum Pharmaceuticals Inc | MIRM | 4.08% | 55.64K | $5.4M |
| 7 | Billiontoone Inc | BLLN | 3.94% | 53.73K | $5.2M |
| 8 | Guardant Health Inc | GH | 3.89% | 30.29K | $5.1M |
| 9 | Cytokinetics Inc | CYTK | 3.65% | 62.24K | $4.8M |
| 10 | United Therapeutics Corp | UTHR | 3.19% | 8.10K | $4.2M |
| 11 | TransMedics Group Inc | TMDX | 3.11% | 43.30K | $4.1M |
| 12 | Axsome Therapeutics Inc | AXSM | 3.08% | 19.40K | $4.1M |
| 13 | Nektar Therapeutics | NKTR | 2.92% | 52.59K | $3.8M |
| 14 | VeraDermics Inc | MANE | 2.89% | 36.77K | $3.8M |
| 15 | Savara Inc | SVRA | 2.84% | 673.02K | $3.7M |
| 16 | ICU Medical Inc | ICUI | 2.79% | 20.20K | $3.7M |
| 17 | Dianthus Therapeutics Inc | DNTH | 2.73% | 32.29K | $3.6M |
| 18 | Trevi Therapeutics Inc | TRVI | 2.68% | 196.67K | $3.5M |
| 19 | Viridian Therapeutics Inc | VRDN | 2.52% | 137.76K | $3.3M |
| 20 | Twist Bioscience Corp | TWST | 1.98% | 18.45K | $2.6M |
| 21 | Palvella Therapeutics Inc | PVLA | 1.89% | 17.83K | $2.5M |
| 22 | Corvus Pharmaceuticals Inc | CRVS | 1.87% | 170.89K | $2.5M |
| 23 | Ceribell Inc | CBLL | 1.66% | 91.33K | $2.2M |
| 24 | Hinge Health Inc | HNGE | 1.22% | 18.18K | $1.6M |
| 25 | Aveanna Healthcare Holdings Inc | AVAH | 1.12% | 109.35K | $1.5M |
Click a ticker to see every ETF that owns it.
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | — | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | — | Last payment | — |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
No distributions in our database for this fund — it may not pay them, or history has not loaded yet.
Risk Statistics
| Volatility 1Y / 3Y | 27.41% / — | Sharpe 1Y / 3Y | 2.93 / — |
| Max drawdown 1Y / 3Y | -16.24% / — | Sortino 1Y | 4.84 |
| Beta vs S&P 500 (3Y) | 1.02 | Correlation vs S&P 500 (1Y) | 0.542 |
| Downside deviation 1Y | 16.59% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 1.40K | Average volume | 4.11K |
| AUM | $74.7M | Premium/Discount | +47.86% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $74.7M → $74.7M |
| 1 Week | $581.3K | +0.78% | $74.7M → $74.7M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for LFSC
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.